We are live on ! Find out more
BLRX

BioLineRX
BLRX

16 hedge funds and large institutions have $5.42M invested in BioLineRX in 2020 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

150% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 2

50% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 2

47% more capital invested

Capital invested by funds: $3.69M → $5.42M (+$1.73M)

23% more funds holding

Funds holding: 13 → 16 (+3)

0.01% less ownership

Funds ownership: 0.04% → 0.03% (-0.01%)

Holders
16
Holders Change
+3
Holders Change %
+23.08%
% of All Funds
0.33%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
3
Reduced
2
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$377K
2
Renaissance Technologies
Renaissance Technologies
New York
+$269K
3
PVH
Psagot Value Holdings
Israel
+$200K
4
Goldman Sachs
Goldman Sachs
New York
+$64.6K
5
Acadian Asset Management
Acadian Asset Management
Massachusetts
+$32.4K

Top Sellers

Rank Fund Capital Flow
1
SM
Senvest Management
New York
-$124K
2
BI
BVF Inc
California
-$79.7K
3
Jane Street
Jane Street
New York
-$77K
4
NFG
Next Financial Group
Texas
-$5K

BLRX Hedge Fund Activity: Q2 2020 in Review

16 of the 4,888 institutional investors tracked by Wall St. Rank reported a position in BioLineRX (BLRX) for Q2 2020, worth a combined $5.42M — up 47% from $3.69M a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new BLRX positions and 2 closed out — a net gain of 3 holders — while 3 added to existing stakes and 2 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $377K. The largest seller was Senvest Management, cutting an estimated $124K.

  • 16 institutional investors held BioLineRX (BLRX) as of Q2 2020, up from 13 in Q1 2020.
  • Funds reported $5.42M of BioLineRX stock for Q2 2020, up 47% quarter-over-quarter.
  • 5 funds opened new BioLineRX positions in Q2 2020 and 2 closed out, a net change of +3 holders.
  • The largest BioLineRX buyer in Q2 2020 was Morgan Stanley, an estimated $377K added.
  • The largest BioLineRX seller in Q2 2020 was Senvest Management, an estimated $124K sold.

Based on aggregated 13F filings for Q2 2020.